FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2594698743> ?p ?o ?g. }

• W2594698743 endingPage "1028" @default.
• W2594698743 startingPage "1021" @default.
• W2594698743 abstract "The primary aim of this study was to describe healthcare costs and utilization during the first year after a diagnosis of acute myeloid leukemia (AML) for privately insured non-Medicare patients in the United States aged 50 to 64 years who were treated with either chemotherapy or chemotherapy and allogeneic hematopoietic cell transplantation (alloHCT). MarketScan (Truven Health Analytics) adjudicated total payments for inpatient, outpatient, and prescription drug claims from 2007 to 2011 were used to estimate costs from the health system perspective. Stabilized inverse propensity score weights were constructed using logistic regression to account for differential selection of alloHCT over chemotherapy. Weighted generalized linear models adjusted costs and utilization (hospitalizations, inpatient days, and outpatient visit-days) for differences in age, sex, diagnosis year, region, insurance plan type, Elixhauser Comorbidity Index), and 60-day prediagnosis costs. Because mortality data were not available, models could not be adjusted for survival times. Among 29,915 patients with a primary diagnosis of AML, 985 patients met inclusion criteria (774 [79%] receiving chemotherapy alone and 211 [21%] alloHCT). Adjusted mean 1-year costs were $280,788 for chemotherapy and $544,178 for alloHCT. Patients receiving chemotherapy alone had a mean of 4 hospitalizations, 52.9 inpatient days, and 52.4 outpatient visits in the year after AML diagnosis; patients receiving alloHCT had 5 hospitalizations, 92.5 inpatient days, and 74.5 outpatient visits. Treating AML in the first year after diagnosis incurs substantial healthcare costs and utilization with chemotherapy alone and with alloHCT. Our analysis informs healthcare providers, policymakers, and payers so they can better understand treatment costs and utilization for privately insured patients aged 50 to 64 with AML." @default.
• W2594698743 created "2017-03-16" @default.
• W2594698743 creator A5000023597 @default.
• W2594698743 creator A5001680440 @default.
• W2594698743 creator A5018744683 @default.
• W2594698743 creator A5019494133 @default.
• W2594698743 creator A5021742756 @default.
• W2594698743 creator A5058862489 @default.
• W2594698743 creator A5058981870 @default.
• W2594698743 creator A5061455564 @default.
• W2594698743 creator A5081856428 @default.
• W2594698743 creator A5084230861 @default.
• W2594698743 date "2017-06-01" @default.
• W2594698743 modified "2023-10-15" @default.
• W2594698743 title "Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation" @default.
• W2594698743 cites W1492609361 @default.
• W2594698743 cites W1998822622 @default.
• W2594698743 cites W2015410846 @default.
• W2594698743 cites W2017908149 @default.
• W2594698743 cites W2019154801 @default.
• W2594698743 cites W2022333024 @default.
• W2594698743 cites W2034333555 @default.
• W2594698743 cites W2034806082 @default.
• W2594698743 cites W2044612846 @default.
• W2594698743 cites W2055638039 @default.
• W2594698743 cites W2057780602 @default.
• W2594698743 cites W2065738117 @default.
• W2594698743 cites W2072447072 @default.
• W2594698743 cites W2076744639 @default.
• W2594698743 cites W2081576971 @default.
• W2594698743 cites W2085502968 @default.
• W2594698743 cites W2092449369 @default.
• W2594698743 cites W2106332501 @default.
• W2594698743 cites W2119148496 @default.
• W2594698743 cites W2130633358 @default.
• W2594698743 cites W2141368628 @default.
• W2594698743 cites W2168639902 @default.
• W2594698743 cites W2169668771 @default.
• W2594698743 cites W2320674515 @default.
• W2594698743 cites W2328997579 @default.
• W2594698743 cites W2336377593 @default.
• W2594698743 cites W2387849425 @default.
• W2594698743 cites W2511633014 @default.
• W2594698743 cites W2528306182 @default.
• W2594698743 doi "https://doi.org/10.1016/j.bbmt.2017.02.017" @default.
• W2594698743 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5497312" @default.
• W2594698743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28263920" @default.
• W2594698743 hasPublicationYear "2017" @default.
• W2594698743 type Work @default.
• W2594698743 sameAs 2594698743 @default.
• W2594698743 citedByCount "36" @default.
• W2594698743 countsByYear W25946987432017 @default.
• W2594698743 countsByYear W25946987432018 @default.
• W2594698743 countsByYear W25946987432019 @default.
• W2594698743 countsByYear W25946987432020 @default.
• W2594698743 countsByYear W25946987432021 @default.
• W2594698743 countsByYear W25946987432022 @default.
• W2594698743 countsByYear W25946987432023 @default.
• W2594698743 crossrefType "journal-article" @default.
• W2594698743 hasAuthorship W2594698743A5000023597 @default.
• W2594698743 hasAuthorship W2594698743A5001680440 @default.
• W2594698743 hasAuthorship W2594698743A5018744683 @default.
• W2594698743 hasAuthorship W2594698743A5019494133 @default.
• W2594698743 hasAuthorship W2594698743A5021742756 @default.
• W2594698743 hasAuthorship W2594698743A5058862489 @default.
• W2594698743 hasAuthorship W2594698743A5058981870 @default.
• W2594698743 hasAuthorship W2594698743A5061455564 @default.
• W2594698743 hasAuthorship W2594698743A5081856428 @default.
• W2594698743 hasAuthorship W2594698743A5084230861 @default.
• W2594698743 hasBestOaLocation W25946987431 @default.
• W2594698743 hasConcept C109159458 @default.
• W2594698743 hasConcept C126322002 @default.
• W2594698743 hasConcept C177713679 @default.
• W2594698743 hasConcept C187212893 @default.
• W2594698743 hasConcept C194828623 @default.
• W2594698743 hasConcept C2426938 @default.
• W2594698743 hasConcept C2776694085 @default.
• W2594698743 hasConcept C2777408962 @default.
• W2594698743 hasConcept C2778729363 @default.
• W2594698743 hasConcept C2778858636 @default.
• W2594698743 hasConcept C28328180 @default.
• W2594698743 hasConcept C2908647359 @default.
• W2594698743 hasConcept C2911091166 @default.
• W2594698743 hasConcept C2993713153 @default.
• W2594698743 hasConcept C45827449 @default.
• W2594698743 hasConcept C54355233 @default.
• W2594698743 hasConcept C71924100 @default.
• W2594698743 hasConcept C86803240 @default.
• W2594698743 hasConcept C98274493 @default.
• W2594698743 hasConcept C99454951 @default.
• W2594698743 hasConceptScore W2594698743C109159458 @default.
• W2594698743 hasConceptScore W2594698743C126322002 @default.
• W2594698743 hasConceptScore W2594698743C177713679 @default.
• W2594698743 hasConceptScore W2594698743C187212893 @default.
• W2594698743 hasConceptScore W2594698743C194828623 @default.
• W2594698743 hasConceptScore W2594698743C2426938 @default.
• W2594698743 hasConceptScore W2594698743C2776694085 @default.
• W2594698743 hasConceptScore W2594698743C2777408962 @default.

• next